X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (89) 89
humans (80) 80
oncology (67) 67
female (37) 37
colorectal neoplasms - drug therapy (34) 34
colorectal neoplasms - genetics (33) 33
mutation (33) 33
colorectal cancer (31) 31
animals (30) 30
cell line, tumor (30) 30
cancer (28) 28
male (25) 25
mice (24) 24
middle aged (24) 24
aged (22) 22
cetuximab (22) 22
antineoplastic agents - pharmacology (21) 21
colorectal neoplasms - pathology (20) 20
drug resistance, neoplasm (20) 20
adult (18) 18
antineoplastic agents - therapeutic use (17) 17
genetic aspects (17) 17
ras proteins - genetics (17) 17
receptor, epidermal growth factor - antagonists & inhibitors (17) 17
therapy (17) 17
aged, 80 and over (16) 16
drug resistance, neoplasm - genetics (16) 16
acquired-resistance (15) 15
chemotherapy (15) 15
proto-oncogene proteins b-raf - genetics (15) 15
proto-oncogene proteins p21 (15) 15
resistance (15) 15
tumors (15) 15
antibodies, monoclonal - therapeutic use (14) 14
beer (14) 14
biochemistry (14) 14
chemistry (14) 14
enzymology (14) 14
metallurgy (14) 14
microbiology (14) 14
mutation or genetic engineering (14) 14
proto-oncogene proteins - genetics (14) 14
spirits (14) 14
vinegar (14) 14
wine (14) 14
lung-cancer (13) 13
mutations (13) 13
analysis (12) 12
breast-cancer (12) 12
cell biology (12) 12
compositions or test papers therefor (12) 12
condition-responsive control in microbiological orenzymological processes (12) 12
health aspects (12) 12
human necessities (12) 12
hygiene (12) 12
kras (12) 12
measuring or testing processes involving enzymes, nucleicacids or microorganisms (12) 12
medical or veterinary science (12) 12
preparations for medical, dental, or toilet purposes (12) 12
processes of preparing such compositions (12) 12
receptor, epidermal growth factor - metabolism (12) 12
antibodies, monoclonal, humanized (11) 11
colon-cancer (11) 11
digestive system diseases (11) 11
egfr (11) 11
expression (11) 11
metastasis (11) 11
multidisciplinary sciences (11) 11
organic chemistry (11) 11
peptides (11) 11
research (11) 11
amplification (10) 10
article (10) 10
cells (10) 10
colorectal neoplasms - metabolism (10) 10
growth-factor receptor (10) 10
neoplasms (10) 10
panitumumab (10) 10
prognosis (10) 10
ras proteins - metabolism (10) 10
receptor, epidermal growth factor - genetics (10) 10
carcinoma (9) 9
care and treatment (9) 9
cell lung-cancer (9) 9
drug resistance, neoplasm - drug effects (9) 9
gene expression regulation, neoplastic (9) 9
genes, ras (9) 9
heterogeneity (9) 9
inhibition (9) 9
neoplasm metastasis (9) 9
neoplasms - drug therapy (9) 9
neoplasms - genetics (9) 9
protein kinase inhibitors - pharmacology (9) 9
proto-oncogene proteins b-raf - antagonists & inhibitors (9) 9
xenograft model antitumor assays (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
biomarkers (8) 8
cell proliferation - drug effects (8) 8
chemosensitivity (8) 8
colorectal carcinoma (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2013, Volume 10, Issue 7, pp. 372 - 374
Tivantinib is being tested in a variety of phase II and phase III clinical trials as a highly selective, non ATP-competitive MET tyrosine kinase inhibitor. Its... 
ARQ 197 | PLACEBO | ONCOLOGY | INIPARIB | KINASE | Proto-Oncogene Proteins c-met - metabolism | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Tubulin Modulators - pharmacology | Humans | Pyrrolidinones - pharmacology | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Quinolines - pharmacology | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 1015 - 1015
Journal Article
Journal Article
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2017, Volume 552, Issue 7683, pp. 1 - 5
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
JAMA, ISSN 0098-7484, 10/2010, Volume 304, Issue 16, pp. 1812 - 1820
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 35, pp. 5705 - 5712
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately... 
GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | PROGNOSTIC-FACTOR | MUTATION STATUS | THERAPY | ONCOLOGY | MISMATCH-REPAIR | OPEN-LABEL | KRAS | GENE COPY NUMBER | CHEMOTHERAPY | Niacinamide - analogs & derivatives | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Phenylurea Compounds | Patient Selection | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Benzenesulfonates - pharmacology | Neoplasm Metastasis | Time Factors | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Cell Survival - drug effects | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Treatment Outcome | Switzerland | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Italy | Aged | Biomarkers, Tumor - genetics | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 10/2014, Volume 7, Issue 1, pp. 86 - 93
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 8 Supplement, pp. 4130 - 4130
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7404, pp. 532 - 536
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 08/2010, Volume 120, Issue 8, pp. 2858 - 2866
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 118 - 122
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably(1,2).... 
GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Gene Library | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | P